Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing
about
Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasisProtein-tyrosine phosphatase 1B modulates early endosome fusion and trafficking of Met and epidermal growth factor receptorsRegulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphataseHepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinaseScatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptorMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibA splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotypeBiology of MET: a double life between normal tissue repair and tumor progressionPak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptorMet receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodiaIdentification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases.Activation of the JNK pathway is essential for transformation by the Met oncogeneDirect interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion.Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells.Dorsal ruffle microdomains potentiate Met receptor tyrosine kinase signaling and down-regulation.The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase.Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancerDistinct recruitment and function of Gab1 and Gab2 in Met receptor-mediated epithelial morphogenesis.Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding.Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3'-kinase-dependent autocrine loop involving hyaluronic acid and CD44.Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation.Molecular characteristics of eight gastric cancer cell lines established in Japan.Tyrosine kinases and gastric cancer.Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase.Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cbl and Gab1.Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversionActivation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.Gab1 is required for cell cycle transition, cell proliferation, and transformation induced by an oncogenic met receptor.Dynamic expression and localization of c-MET isoforms in the developing rat pancreas.A novel isoform of met receptor tyrosine kinase blocks hepatocyte growth factor/Met signaling and stimulates skeletal muscle cell differentiation.Met receptor-induced Grb2 or Shc signals both promote transformation of intestinal epithelial cells, albeit they are required for distinct oncogenic functions.The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinomaCoexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.Proto-oncogene and growth factor/receptor expression in the establishment of primary human non-small cell lung carcinoma cell lines.Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene.Crosstalk between hepatocyte growth factor and integrin signaling pathways.Value of c-Met for Predicting Progression of Precancerous Gastric Lesions in Rural Chinese Population.
P2860
Q24292477-7FDDB50F-3CAB-4F8A-8284-15330533DE9EQ24295233-D773B037-1AA2-4C3B-9EE8-732FF410E1F8Q24316395-36915BA0-7397-4269-A0D3-E8A33AB6EA37Q24329131-074E5EAD-924D-461C-B08A-3893B44439D0Q24554529-4F24B80E-86AA-4FD3-AB40-E5A3472AD630Q24564783-DCA52FA0-167C-4EAF-A02F-5CC870667FB4Q24646295-584D5083-B2D8-4A8D-B9BB-30CE9947B7A2Q24648317-632357A0-DC27-4A8E-851E-490714247915Q28085247-309BBCC7-E641-47EA-AE04-66FA373DFA6BQ28238303-E6DD865B-B5EA-4CAB-AC7C-D2B84194DD7DQ30010161-301E9155-3F95-4F92-8612-CB7A86E3B541Q30168876-B2D81454-9C41-4A3F-A110-E4B57562BA73Q30176542-74E2463F-D4F1-4D73-BFED-6B59228FB61BQ30445760-30C4DC65-5E6E-449F-A14C-4BD62D588868Q30446159-C6AAA334-97BC-484C-AF90-08D8910FD857Q30495866-6B722A70-EAFC-481B-A566-A92A2C8F61A6Q33605698-5C11B12F-BDA8-4616-9191-C8EF1B7151F4Q33890758-D4AA1E0F-7C0C-4BD4-A02C-9A4499B17D5BQ33899291-72295BFC-4ED8-4162-A5C6-C0F22A47E582Q33938013-E6AE8429-ABB6-4EBC-AEA7-A65729546E08Q33963349-F04729EB-34D2-407C-AFC9-E599C4EBB38DQ34097397-4CE4527B-CC04-40A7-9406-0E83B7B783EEQ34099128-B583B35B-7385-48D5-9D6E-62A0CDD22191Q34103663-59BB4689-7137-4262-A75E-D476CFED6362Q34236834-DDF2E535-4CC4-40BD-9AF4-30A463FAD722Q34358610-ECF6F33C-CFA0-41A1-A28B-1F354F5B99ACQ34434226-DBA4FD10-D23B-4DDA-80A8-5BF5BDBC7857Q34764852-A2FE2A39-2D8F-4897-AB59-4D5A0F3C6546Q34785157-94F2BAD7-FB89-4377-BD81-E8DD3742F047Q35010265-AB4457D2-34A2-48E0-B24A-5A24930D212CQ35038349-40667B88-695C-42D8-AEBC-3378D4DE2313Q35121348-7012C7E5-FEBA-4030-B1E4-60A1DA47E1BCQ35141465-0D7B09EF-B08E-4230-B1C2-978F996971A7Q35563524-0BAB9D54-25DB-4D41-97E4-2A60CE6FF57FQ35753107-74FF383B-36B4-4E8F-877B-557D256E89CBQ35773856-F7BB0E5A-F9C8-4E07-BF96-FB7061E356FEQ35832227-4B42B7CD-8F5E-4001-95AE-83465E90670BQ36065558-291633F8-CFB4-4E71-8842-82DD540DDF4CQ36404210-C66700CD-F006-45C9-A5AE-E6FFD1136E77Q36563092-3C00DF22-E147-41D6-BD29-17CC8C1AE312
P2860
Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing
description
1991 nî lūn-bûn
@nan
1991 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Alternative splicing generates ...... ndergo differential processing
@ast
Alternative splicing generates ...... ndergo differential processing
@en
Alternative splicing generates ...... dergo differential processing.
@nl
type
label
Alternative splicing generates ...... ndergo differential processing
@ast
Alternative splicing generates ...... ndergo differential processing
@en
Alternative splicing generates ...... dergo differential processing.
@nl
prefLabel
Alternative splicing generates ...... ndergo differential processing
@ast
Alternative splicing generates ...... ndergo differential processing
@en
Alternative splicing generates ...... dergo differential processing.
@nl
P2093
P2860
P356
P1476
Alternative splicing generates ...... ndergo differential processing
@en
P2093
P2860
P304
P356
10.1128/MCB.11.6.2962
P407
P577
1991-06-01T00:00:00Z